Home/Pipeline/ANPD001

ANPD001

Parkinson's Disease

Phase 2Active

Key Facts

Indication

Parkinson's Disease

Phase

Phase 2

Status

Active

Company

Aspen Neuroscience

About Aspen Neuroscience

Aspen Neuroscience is pioneering a first-in-class, autologous iPSC-derived neuron replacement therapy for Parkinson's disease. The company has developed a scalable manufacturing platform utilizing automation and robotics to make personalized cell therapy commercially viable. Backed by significant venture funding and a seasoned team, Aspen is advancing ANPD001 toward Phase 3 trials and is positioned as a leader in the regenerative medicine space for neurological disorders. Its approach aims to address the root cause of Parkinson's by replacing lost dopamine neurons using a patient's own cells.

View full company profile

Therapeutic Areas

Parkinson's Disease

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active